The global liposomal doxorubicin market attained a value of USD 1.3 billion in 2023, driven by the rising cases of breast and ovarian cancers across the globe. The market is further expected to ...

Researchers engineered a nanobody-conjugated liposome (A5-LNP-DOX) that targets CD155 and delivers doxorubicin directly to ...

The global liposomal doxorubicin market size is expected to reach USD 1.89 billion by 2030, registering a CAGR of 6.3% from 2024 to 2030 ...

Liposomal doxorubicin is one such option, and this study found that it had lower cardiotoxicity than doxorubicin alone. This finding supports the use of liposomal doxorubicin in patients at a high ...

The Liposomal Doxorubicin Market is estimated to be valued at USD 1,281.3 million in 2024. Demand is predicted to rise at a CAGR of 6.3% from 2024 to 2034. The market is anticipated to reach USD 2,367 ...

Lantern Pharma Inc. (NASDAQ: LTRN), a pioneering artificial intelligence (AI) company transforming oncology drug discovery and development, today announced the launch of an innovative AI-powered ...

The Liposomal Doxorubicin Market encompasses the global industry involved in the production, distribution, and utilization of liposomal formulations of the chemotherapy drug doxorubicin. Liposomal ...

The shares of this leading pharmaceutical company are in focus after the company secured the USFDA's approval for its key ...

Doxorubicin Hydrochloride Liposome Injection is indicated for treatment of ovarian cancer, acquired immune deficiency syndrome (AIDS)-related Kaposi's Sarcoma and multiple myeloma.

According to IQVIA, the market for Doxorubicin Hydrochloride Liposome Injection is estimated at $29 million for the twelve months ending March 2025.

Lupin’s alliance partner, ForDoz has received approval from the Food and Drug Administration for doxorubicin hydrochloride liposome injection, 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL ...